Welcome to our dedicated page for Serina Therapeutics news (Ticker: SER), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Serina Therapeutics, Inc. (SER) news is centered on a clinical-stage biotechnology company developing the POZ Platform™ drug optimization technology and SER-252 for advanced Parkinson’s disease. Company updates often focus on clinical study progress, safety monitoring, tolerability observations, pharmacokinetic findings, and exploratory measures related to motor function.
The most important Serina news themes involve the Phase 1b registrational study of SER-252, including cohort dosing, Safety Monitoring Committee review, dose-escalation decisions, and observations tied to sustained apomorphine exposure. Because SER-252 is the company’s main named product candidate, clinical updates are closely tied to how the POZ Platform is being tested in a neurological disease setting.
Serina also reports financial results and business updates, securities financing activity, board and governance changes, and biotechnology conference participation. Research-related announcements may include POZ Platform applications across small molecules, RNA-based therapeutics, antibody-based drug conjugates, and lipid nanoparticle delivery formulations. Company materials also discuss partnership routes such as out-licensing, co-development, and a non-exclusive Pfizer license involving POZ polymer technology for lipid nanoparticle drug delivery formulations.
For SER stock research, key news categories include SER-252 clinical development, POZ Platform research, regulatory and financing disclosures, and corporate updates that affect how the company advances its wholly owned drug candidates and external platform applications.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company focused on its proprietary POZ Platform™ drug optimization technology, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. CEO Steve Ledger will engage in a fireside chat on Tuesday, July 29, 2025, at 2:00 p.m. ET during the two-day conference scheduled for July 29-30, 2025.
Serina Therapeutics (NYSE American: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to a new non-executive employee. The inducement grant consists of options to purchase 12,500 shares of common stock, with an exercise price matching the closing price on June 18, 2025.
The Option Grant, approved by Serina's Compensation Committee under the 2024 Inducement Equity Plan, aims to align employee interests with stockholders and was made in compliance with NYSE American's Company Guide Section 711(a).
Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company, has announced its 2025 Annual Stockholders Meeting will be held on November 7, 2025. The specific time and location will be detailed in the company's definitive proxy statement to be filed with the SEC.
Due to the meeting date change of more than 30 days from the 2024 annual meeting anniversary, stockholder proposals under Rule 14a-8 must be submitted by 5:00 p.m. (Central Time) on August 15, 2025. For stockholder proposals and director nominations under the company's bylaws, submissions must be received between July 10, 2025, and August 9, 2025 at the company's Huntsville, Alabama headquarters.
Serina Therapeutics (NYSE American: SER) announced its CEO Steve Ledger will present at a FORCE Family Office investor webinar on June 26, 2025, at 12:00 p.m. ET. The presentation, titled "New Drug Optimization Platform to Transform Parkinson's Care," will focus on the company's drug candidate SER-252, a polymer conjugate of apomorphine designed to provide continuous dopaminergic stimulation for Parkinson's disease treatment.
The webinar will highlight the company's POZ Platform™ technology and its potential to improve safety, duration, and tolerability of Parkinson's treatments. The event will include a Q&A session hosted by FORCE Family Office CEO Steve Saltzstein.
Serina Therapeutics (NYSE: SER) has appointed Dr. Stephen Brannan to its Board of Directors. Dr. Brannan brings over 30 years of experience in neuroscience and neuropsychiatry drug development. He most recently served as Chief Medical Officer at Karuna Therapeutics, where he led the clinical development of KarXT, the first new schizophrenia treatment mechanism in over 30 years, which contributed to Karuna's $14 billion acquisition by Bristol Myers Squibb in 2024.
Dr. Brannan's extensive experience includes senior leadership roles at Takeda, Novartis, Cyberonics, and Eli Lilly, where he directed clinical programs in various CNS conditions. He will support Serina's strategic development of long-acting CNS therapeutics using their proprietary POZ Platform™ technology. The company also announced the departure of Remy Gross from its Board, who will continue supporting the team in a consulting role.
Serina Therapeutics (NYSE: SER), a clinical-stage biotech company developing SER-252 for advanced Parkinson's disease, has granted stock options to two new non-executive employees. The grants, totaling 15,000 shares of common stock, were made on March 20, 2025, with an exercise price matching the closing stock price on that date.
The Option Grants, approved by Serina's Compensation Committee under the 2024 Inducement Equity Plan, will vest over four years: 25% after the first year and the remaining 75% in three equal annual installments, subject to continued employment. These grants were made as employment inducements in compliance with NYSE American's Company Guide Section 711(a).
Serina's proprietary POZ Platform™ technology enables drug optimization for their lead candidate.